ISSN:
1569-8041
Keywords:
chemoradiotherapy
;
combined modality treatment
;
non-small-cell lung cancer
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Background:Although chemoradiotherapy is standard treatment forunresectable stage III non-small-cell lung cancer (NSCLC), few long-termsurvival data exist. Patients and methods:Between October 1989 and December 1991, 74patients with histologically or cytologically proven NSCLC, unresectable stageIIIA or IIIB, were entered into this study. Seventy patients were eligible andevaluable for response, toxicity, and survival analysis. Chemotherapyconsisted of cisplatin (100 mg/m2 on days 1, 29, and 57) andvindesine (3 mg/m2 on days 1, 8, 29, 36, 57, and 64). Thoracicradiotherapy was administered for two weeks (2 Gy given 10 times, fivefractions per week), and after a 14-day rest period, the previous schedule ofradiotherapy was repeated for two weeks. A 10-Gy to 20-Gy dose of radiotherapywas administered during the third cycle of chemotherapy. Results:Of the 70 evaluable patients, 1 (1.4%) hada complete response (CR) and 51 (72.9%) had a partial response (PR).The median survival time was 14.8 months, and the five-year survival rate was14.8%. The major toxicity was leukopenia (≥ grade 3, 93%).Other toxicities ≥ grade 3 included anemia (34%),nausea/vomiting (27%), alopecia (7%), thrombocytopenia(4%), and serum creatinine elevation (1%). Treatment relateddeath occurred in two patients (2.8%). One patient died of pneumoniaand pneumothorax, and the other of hemoptysis. Conclusions:Concurrent chemotherapy and radiotherapy has thepotential to provide long-term survival with acceptable toxicities.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1023/A:1008328207137
Permalink
